MRGPRX2 is a promiscuous receptor on mast cells that responds to a variety of exogenous and endogenous ligands, including Cortistatin 14 (CST-14), Compound 48/80 (Cpd 48/80) and a variety of pharmacological agents. It mediates IgE-independent degranulation and has been implicated in multiple mast cell-mediated disorders, such as chronic urticaria, atopic dermatitis, and pain disorders. Atheron discovered a novel, potent, and selective orally active small molecule MRGPRX2 antagonist, ATH-097 for potential treatment of mast cell-mediated disease.

ATH-097 potently inhibits MRGPRX2-mediated mast cell degranulation in vitro and in vivo

Session details
Session type: Flash Talks (FT)
Session number: FT25
Session title: Mastocytosis
Session date: Monday 15 June 2026
Session time: 10:45-12:15
Session room: Room Athens